Study to Assess NBI-1065845 for Major Depressive Disorder (H-56900)

A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

If your current antidepressant medication(s) is/are not adequately improving symptoms of your MDD, you may be eligible for the AMPA Vega-2 Study.

Participation in the study may last about three years and includes 42 study site visits. All participants will be able to remain on their current antidepressant medication(s) while taking part. Reimbursement may be available for applicable travel costs and inconveniences.

To participate in this study, you must:

1. Be at least 18 years old
2. Have a primary diagnosis of MDD
3. Be currently receiving at least 1 antidepressant medication
4. Have had inadequate response to up to 5 oral antidepressant medications
5. Not be pregnant, breastfeeding, or planning to become pregnant during the study